Brain stem infarction

Summary

Brain stem infarction (MONDO:0006686) is a disease and 5 clinical trials. Top therapeutic interventions include botulinum toxin type a. A subtype of brain infarction — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	brain stem infarction
Mondo ID	MONDO:0006686
EFO	EFO:1000847
MeSH	D020526
DOID	DOID:3523
SNOMED CT	95457000
UMLS	C0521542
MedGen	101068
Anatomy (UBERON)	UBERON:0002298
Is cancer (heuristic)	no

Also known as: brain infarction of brainstem · brainstem brain infarction

Disease family

This is a subtype of brain infarction. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › cerebrovascular disorder › brain infarction › brain stem infarction

Related subtypes (2): cerebral infarction, MRI defined brain infarct

Subtypes (1): lateral medullary syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00912041	Not specified	RECRUITING	BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
NCT05470478	Not specified	NOT_YET_RECRUITING	iBCI Optimization for Veterans With Paralysis
NCT05724173	Not specified	RECRUITING	Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia
NCT06094205	Not specified	RECRUITING	Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
NCT06196606	Not specified	RECRUITING	Effect of Botulinum Toxin Injection Into Upper Esophageal Sphincter in Patients With Medullary Infarction

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BOTULINUM TOXIN TYPE A	4	1